Combined treatment of TROP‑2 targeted CAR-T and vascular disruptor CBP enhances anti‑tumor activity in triple‑negative breast cancer.

CAR-T cells - Chinese PLA General Hospital

sotuletinib (BLZ-945) - Novartis, BMS

http://www.ncbi.nlm.nih.gov/pubmed/42214174

JiaHu; Fengjun Xiao; Jian Jiang; Jingjin Zhu; Li Zhu; Lisheng Wang; Peng Jiao; Weiyuan Zhang; Xiru Li; Yiming Wang; Yizhu Chen; Yufan Wei

May 30, 2026